Cloperastine

Cloperastine
Systematic (IUPAC) name
1-[2-[(4-Chlorophenyl)-phenyl-methoxy]ethyl]piperidine
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration		 Oral
Identifiers
CAS Number 3703-76-2 YesY
ATC code R05DB21 (WHO)
PubChem CID 2805
DrugBank DB09002 N
ChemSpider 2703 YesY
UNII 69M5L7BXEK YesY
KEGG D03557 YesY
ChEMBL CHEMBL415087 YesY
Synonyms HT-11
Chemical data
Formula C20H24ClNO
Molar mass 329.863 g/mol
 NYesY (what is this?)  (verify)

Cloperastine (INN) or cloperastin, also known as cloperastine hydrochloride (JAN) (brand names Hustazol, Nitossil, Seki) and cloperastine fendizoate (or hybenzoate), is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries.[1][2][3] It was first introduced in 1972 in Japan, and then in Italy in 1981.[4] The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the σ1 receptor (Ki = 20 nM) (likely an agonist),[5] GIRK channel blocker (described as "potent"),[6][7][8][9] antihistamine (Ki = 3.8 nM for the H1 receptor),[3][5] and anticholinergic.[3][10] It is thought that the latter two properties contribute to side effects, such as sedation and somnolence, while the former two may be involved in or responsible for the antitussive efficacy of cloperastine.[5][6]

See also

References

  1. ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 301–. ISBN 978-1-4757-2085-3.
  2. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 261–. ISBN 978-3-88763-075-1.
  3. 1 2 3 Cuzzocrea, Salvator; Catania, Maria (2011). "Pharmacological and clinical overview of cloperastine in treatment of cough". Therapeutics and Clinical Risk Management: 83. doi:10.2147/TCRM.S16643. ISSN 1178-203X.
  4. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1103–. ISBN 978-0-8155-1856-3.
  5. 1 2 3 Gregori-Puigjane, E.; Setola, V.; Hert, J.; Crews, B. A.; Irwin, J. J.; Lounkine, E.; Marnett, L.; Roth, B. L.; Shoichet, B. K. (2012). "Identifying mechanism-of-action targets for drugs and probes". Proceedings of the National Academy of Sciences 109 (28): 11178–11183. doi:10.1073/pnas.1204524109. ISSN 0027-8424.
  6. 1 2 K. Fan Chung; John Widdicombe (30 September 2008). Pharmacology and Therapeutics of Cough. Springer Science & Business Media. pp. 230–. ISBN 978-3-540-79842-2.
  7. ↑ Soeda, Fumio; Fujieda, Yoshiko; Kinoshita, Mizue; Shirasaki, Tetsuya; Takahama, Kazuo (2016). "Centrally acting non-narcotic antitussives prevent hyperactivity in mice: Involvement of GIRK channels". Pharmacology Biochemistry and Behavior 144: 26–32. doi:10.1016/j.pbb.2016.02.006. ISSN 0091-3057.
  8. ↑ YAMAMOTO, Gen; SOEDA, Fumio; SHIRASAKI, Tetsuya; TAKAHAMA, Kazuo (2011). "Is the GIRK Channel a Possible Target in the Development of a Novel Therapeutic Drug of Urinary Disturbance?". YAKUGAKU ZASSHI 131 (4): 523–532. doi:10.1248/yakushi.131.523. ISSN 0031-6903.
  9. ↑ KAWAURA, Kazuaki; HONDA, Sokichi; SOEDA, Fumio; SHIRASAKI, Tetsuya; TAKAHAMA, Kazuo (2010). "A Novel Antidepressant-like Action of Drugs Possessing GIRK Channel Blocking Action in Rats". YAKUGAKU ZASSHI 130 (5): 699–705. doi:10.1248/yakushi.130.699. ISSN 0031-6903.
  10. ↑ Andrejus Korolkovas (16 August 1988). Essentials of Medicinal Chemistry. Wiley. ISBN 978-0-471-88356-2.


This article is issued from Wikipedia - version of the Friday, April 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.